100 completed, 31 terminated, 12 withdrawn, 9 unknown. 81 Phase 2, 60 Phase 1, 26 Not applicable, 7 Phase 3, 2 Early Phase 1.
Follow Stage IV Non-Small Cell Lung Cancer: new trials by email Literature Review of Stage IV Non-Small Cell Lung Cancer trials Research Report on Stage IV Non-Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC Circulating Tumor-Specific T Cell Nanodetection Technology (CTT-NanoDT) - Non-Small Cell Lung Cancer, Lung Adenocarcinoma | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 80 | 2026-04-01 | 2026-02-06 | |
| PALACE: Cemiplimab Trial According to ctDNA Levels Cemiplimab, Carboplatin, Paclitaxel - Non Small Cell Lung Cancer Metastatic, Lung Diseases | Phase 2 | Recruiting | Fundación GECP | 63 | 2025-07-29 | 2025-11-19 |
| Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. Non Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Recruiting | Gene Solutions | 50 | 2023-12-04 | 2025-07-16 | |
| Patient-centered, Optimal Integration of Survivorship and Palliative Care POISE - Stage IV Non-small Cell Lung Cancer, Targeted Therapy | Not applicable | Recruiting | Massachusetts General Hospital | 70 | 2023-09-29 | 2025-11-24 |
| Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide - Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2023-03-10 | 2026-09-16 |
| CISH Inactivated TILs in the Treatment of NSCLC Fludarabine, Cyclophosphamide, CISH Inactivated TIL - Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Intima Bioscience, Inc. | 2023-02-01 | 2026-02-23 | |
| Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer BMF-219 - Non Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Terminated | Biomea Fusion Inc. | 13 | 2023-01-12 | 2025-02-07 |
| Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma Serplulimab and Bevacizumab injection - Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 50 | 2023-01-10 | 2023-01-09 |
| SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC SBRT+Osimertinib, Osimertinib 80 MG - Stage IV Non-small Cell Lung Cancer | Not applicable | Unknown | Li Zhang | 72 | 2023-01-01 | 2022-10-17 |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer IOV-4001 - Unresectable Melanoma, Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 53 | 2022-07-20 | 2026-06-11 |
| Ruxolitinib for Cancer Cachexia Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. - Stage IV Non-small Cell Lung Cancer, Cachexia | Early Phase 1 | Active not recruiting | Tu Dan | 10 | 2022-02-23 | 2026-07-07 |
| Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer Hypofractionated Stereotactic Radiotherap - Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | First People's Hospital of Hangzhou | 21 | 2022-01-01 | 2022-10-20 |
| Randomized Controlled Clinical Study of Drug Therapy Combined With Thoracic Radiotherapy for Non-oligometastatic NSCLC Thoracic Three-dimensional Radiotherapy - Stage IV Non-small Cell Lung Cancer | Not applicable | Unknown | Guizhou Medical University | 88 | 2021-12-30 | 2022-01-04 |
| Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer ONO-7475, Osimertinib Mesylate - Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 78 | 2021-08-06 | 2026-03-13 |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer Educational Video and QPL List, Usual Care - Stage IV Melanoma, Advanced Lung Cancer | Not applicable | Completed | Massachusetts General Hospital | 199 | 2021-01-23 | 2026-08-25 |
| Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors ImmunicomAIAC - Stage IV Non-small Cell Lung Cancer, Stage IV Melanoma | Phase 1 | Unknown | Dr. Ronnie Shapira | 30 | 2020-02-24 | 2021-03-24 |
| Study of Crizotinib for ROS1 and MET Activated Lung Cancer Crizotinib - Non-squamous Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 2 | Completed | University Health Network, Toronto | 33 | 2019-12-03 | 2026-06-23 |
| Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments Plasma sample collection - Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma | Active not recruiting | OncoHost Ltd. | 10000 | 2019-10-01 | 2026-10-19 | |
| Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites Canady Helios Cold Plasma Scalpel - Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer | Not applicable | Unknown | Jerome Canady, M.D. | 20 | 2019-07-30 | 2021-08-09 |
| Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy eHealth system support for symptom management via CANKADO - Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer | Completed | iOMEDICO AG | 154 | 2019-07-10 | 2021-10-05 |
Showing 20 of 166. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (166) · Breast Neoplasms (17) · Adenocarcinoma of Lung (15) · Pancreatic Neoplasms (15) · Squamous Cell Carcinoma of Head and Neck (14) · Carcinoma, Renal Cell (13) · Colonic Neoplasms (12) · Lung Neoplasms (12) · Rectal Neoplasms (12) · Melanoma (11) · Small Cell Lung Carcinoma (11) · Salivary Gland Neoplasms (10) · Carcinoma, Ovarian Epithelial (9) · Stomach Neoplasms (9) · Brain Neoplasms (7)
Carcinoma, Bronchogenic (166) · Neoplasms by Site (166) · Respiratory Tract Diseases (166) · Bronchial Neoplasms (165) · Respiratory Tract Neoplasms (165) · Thoracic Neoplasms (165) · Lung Diseases (164) · Neoplasms (161) · Lung Neoplasms (154) · Neoplasms by Histologic Type (52) · Neoplasms, Glandular and Epithelial (48) · Carcinoma (45) · Adenocarcinoma (34) · Urogenital Diseases (26) · Urogenital Neoplasms (25)
Carboplatin (26) · Erlotinib Hydrochloride (20) · Paclitaxel (18) · Docetaxel (15) · Taxes (15) · Gemcitabine (14) · Pemetrexed (13) · pembrolizumab (11) · Cisplatin (10) · Nivolumab (8) · Bevacizumab (7) · Cetuximab (7) · Bortezomib (6) · Radiosurgery (5) · 1,2-diaminocyclohexaneplatinum II citrate (4)
National Cancer Institute (NCI) (54) · Wake Forest University Health Sciences (7) · Roswell Park Cancer Institute (5) · Jonsson Comprehensive Cancer Center (4) · Mayo Clinic (4) · Stanford University (4) · University of Washington (4) · Albert Einstein College of Medicine (3) · Barbara Ann Karmanos Cancer Institute (3) · City of Hope Medical Center (3) · Emory University (3) · Ohio State University Comprehensive Cancer Center (3) · SWOG Cancer Research Network (3) · University of Southern California (3) · Eli Lilly and Company (2)
United States (130) · Canada (7) · China (6) · France (3) · Israel (3) · Spain (3) · Germany (2) · Japan (2) · Belgium (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · India (1) · Mexico (1) · Netherlands (1)
Alex Adjei (5) · Edward Garon (4) · Angela Davies (2) · David Camidge (2) · Julie Brahmer (2) · Karen Kelly (2) · Karen Reckamp (2) · Laura A Petrillo, MD (2) · Miguel Villalona-Calero (2) · Missak Haigentz (2) · Roman Perez-Soler (2) · William Petty (2) · Abed Agbaria, MD (1) · Adam Berger, MD (1)
PMID 17167137, PMID 22586682, PMID 22949150, PMID 23475103, PMID 24100924, PMID 24246704, PMID 25965900, PMID 26062933, PMID 26611425, PMID 27491498, PMID 28598227, PMID 28950351, PMID 28973074, PMID 29874546, PMID 30497431, PMID 30850872, PMID 31806360, PMID 31931024, PMID 33021871, PMID 33608212, PMID 33636454, PMID 33885704, PMID 34385708, PMID 34629425, PMID 34749008, PMID 35130505, PMID 35254001, PMID 35365139, PMID 35429391, PMID 35604701, PMID 35771552, PMID 35898703, PMID 36228177, PMID 36279134, PMID 36827396, PMID 36854570, PMID 37105304, PMID 37393762, PMID 37509349, PMID 37594667, PMID 37770704, PMID 37788414, PMID 38513170, PMID 39325429, PMID 39938469, PMID 40511978, PMID 40973049, PMID 41114938, PMID 41681846
U10CA032102 (6), N01CM62209 (5), U10CA021115 (5), N01CM62201 (4), P30CA012197 (4), U01CA076576 (4), U10CA025224 (4), N01CM62208 (3), P30CA006973 (3), P30CA013330 (3), P30CA016672 (3), P30CA022453 (3), P30CA093373 (3), U10CA031946 (3), N01CM00039 (2)